يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Orti Pascual, Guillem"', وقت الاستعلام: 1.46s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Murthy GSG Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. Kim S Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA. CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. Estrada-Merly N CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. Abid MB Divisions of Hematology/Oncology and Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. Aljurf M Department of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia. Assal A Columbia University Irving Medical Center, Department of Medicine, Bone Marrow Transplant and Cell Therapy Program, New York, NY, USA. Ortí G Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Haematologica;108(7); https://doi.org/10.3324/haematol.2022.281958Test; Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Jul;108(7):1900–8.; https://hdl.handle.net/11351/9978Test

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Jiménez M, Roldán E, Gironella M, Fox L, Orti G, Barba P, Valcárcel D, Bosch F, Abrisqueta P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Fernández-Naval C, Pumarola T, Esperalba J Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Villacampa G Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martinez-Gallo M, Hernández M Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Crespo M Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Cabirta A, Catalá E, Valentín M, Marín-Niebla A Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Orfao A Department of Medicine and Cytometry General ServiceNucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain. González M Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC–CB16/12/00233 and Center for Cancer Research–IBMCC (USAL-CSIC), Salamanca, Spain. Campins M Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ruiz-Camps I Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Advances;6(3); https://doi.org/10.1182/bloodadvances.2021006101Test; Jimenez M, Roldan E, Fernandez-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774–84.; https://hdl.handle.net/11351/8614Test; 000754263400007

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Ruiz de Morales JMG Inmunology Unit, Complejo Asistencial Universitario e Instituto de Biomedicina Universidad de León (IBIOMED), León, Spain. Puig L Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Daudén E Dermatology Department, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Hospital Universitario de la Princesa, Madrid, Spain. Cañete JD Arthritis Unit, Rheumatology Dpt.,Hospital Clinic and IDIBAPS, Barcelona, Spain. Pablos JL Rheumatology Department, Hospital 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain. Martín AO Gastroenterology Department, La Paz Universitary Hospital, Madrid, Spain. Montalbán X Servei de Neurologia/Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Borruel N Unitat d’Atenció Crohn-Colitis, Unitat de Recerca en Aparell Digestiu, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Ortí G Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Autoimmunity Reviews;19; https://doi.org/10.1016/j.autrev.2019.102429Test; Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2020 Jan;19:102429.; https://hdl.handle.net/11351/6373Test; 000508749200008